What does tumor mutational burden mean for HER2-Positive Breast Cancer immunotherapy

Tumor Mutational Burden (TMB) and HER2-Positive Breast Cancer: What You Need to Know

I appreciate this question because it highlights an important gap in how we think about HER2-positive breast cancer treatment. Let me explain what TMB means and why it's less central to HER2-positive breast cancer care than it might be for other cancers.

What is Tumor Mutational Burden (TMB)?

Tumor mutational burden is essentially a count of how many mutations (changes in DNA) exist in your cancer cells. Think of it like this: if your cancer's DNA were a book, TMB measures how many typos or changes appear throughout that entire book.

According to the CancerPatientLab webinar on immunotherapy biomarkers, TMB was approved by the FDA in 2020 as a "tissue-agnostic biomarker"—meaning it can apply to many cancer types, not just one specific type. The theory is straightforward: tumors with more mutations create more "foreign-looking" signals that can activate your immune system, making immunotherapy more likely to work.

Why TMB Matters Less for HER2-Positive Breast Cancer

Here's the critical distinction: HER2-positive breast cancer has a very different treatment strategy than cancers where TMB is the primary decision-maker.

According to NCCN Guidelines for breast cancer, HER2-positive tumors respond exceptionally well to HER2-targeted therapies (drugs like trastuzumab/Herceptin, pertuzumab/Perjeta, and newer agents like trastuzumab deruxtecan). These targeted therapies work by directly attacking the HER2 protein on cancer cells—they don't depend on how many total mutations your cancer has.

The clinical reasoning: When oncologists identify HER2-positive breast cancer, they typically prioritize HER2-targeted therapy first because:

• These drugs have proven, durable responses in HER2-positive disease
• They work through a direct mechanism (blocking HER2 signaling)
• TMB status doesn't change this recommendation

When TMB Might Be Relevant for HER2-Positive Breast Cancer

TMB could potentially matter in these scenarios:

1. Triple-Negative Breast Cancer (TNBC) Context If your HER2-positive cancer also lacks hormone receptors (ER/PR negative), immunotherapy becomes more relevant. In that case, TMB-high status might support considering immunotherapy options, though this would be unusual for HER2-positive disease.

2. Advanced/Metastatic Disease If your HER2-positive cancer has progressed despite HER2-targeted therapy, your oncologist might explore immunotherapy combinations. In that setting, TMB could provide additional information about immune responsiveness.

3. Combination Approaches Emerging research is exploring whether combining HER2-targeted therapy with immunotherapy improves outcomes. TMB status might inform these decisions, though HER2 status remains the primary driver.

The Bottom Line: Questions for Your Oncologist

If you have HER2-positive breast cancer and TMB testing has been mentioned, ask your care team:

1. "Why is TMB testing being recommended for my specific situation?" (This helps clarify if there's something unusual about your case)

2. "How will my TMB result change my treatment plan?" (This gets at whether it's truly actionable for you)

3. "Are we considering immunotherapy in addition to HER2-targeted therapy, and if so, why?"

4. "What is my HER2 status, and what HER2-targeted therapies are recommended first?" (This should be the primary focus)

5. "Do I have any other biomarkers (like hormone receptor status, PD-L1, or microsatellite instability) that might affect treatment decisions?"

Important Context

According to NCCN Guidelines, the standard approach for HER2-positive breast cancer emphasizes HER2-directed therapy as the foundation of treatment. While immunotherapy is an active area of research in breast cancer, TMB alone is not typically the deciding factor for HER2-positive disease the way it might be for other cancer types.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.